Objective      To investigate the clinical efficacy of transurethral resection surgery in treatment of superficial bladder cancer combined with benign prostate hyperplasia (BPH).       Methods      A retrospective analysis of 109 patients with superficial bladder cancer combined with BPH treated in our hospital was conducted. The pati

ents were divided into 2 groups: combined treatment group (n=57) that patient undertook the treatment of transurethral resection of bladder (TURBt) and transurethral resection of prostate (TURP)

and control group (n=52) that patients only had TURBt. The perioperative indicators were compared between the 2 groups.       Results      The operative time

blood loss

postoperative indwelling catheter time and hospital stay were longer in combined group than control group

and the difference was statistically significant (P0.05). After operation

patients in combined group had significant lower marks compared with control group by evaluation of the International Prostate Symptom Score (IPSS)

quality of life (QOL) score and residual urine volume (PVR) value (P0.05). Q

max

value of the combined group was significantly higher in patients (P0.05). After 24 months of operation

the recurrence rate was not significant difference between two groups (P0.05). In combined group

the incidence of urethral stricture was 3.51%

which was much lower than that in control group (17.31%). The obvious difference was statistically significant (P0.05).       Conclusion      Compared to TURBt treatment alone

combined treatment had a longer operative- and postoperative recovery-time

and more bleeding in treatment of superficial bladder cancer combined with BPH. Nevertheless

combined treatment is beneficial for patients with relieved postoperative difficulty in voiding

improved quality of life and reduced incidence of urethral stricture.